Special Issue "Structure and Function of Podoplanin (PDPN) in Disease"

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: 31 March 2020.

Special Issue Editor

Prof. Yukinari Kato
E-Mail Website
Guest Editor
Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2‐1 Seiryo‐machi, Aoba‐ku, Sendai, Miyagi 980‐8575, Japan
Interests: monoclonal antibody (mAb); antibody therapy; podoplanin (PDPN); cancer-specific mAb (CasMab); anti-glycopeptide mAb (GpMab); cell-based immunization and screening (CBIS)

Special Issue Information

Dear Colleagues,

Podoplanin (PDPN), also known as T1alpha or Aggrus, is a type I transmembrane sialoglycoprotein that is expressed not only in normal tissues, such as pulmonary type I alveolar cells, renal podocytes, and lymphatic endothelial cells, but also in cancer tissues, including brain tumor, malignant mesothelioma, oral cancer, and lung cancer. PDPN is associated with tumor cell-induced platelet aggregation and hematogenous metastasis through interactions with the C-type lectin-like receptor 2 (CLEC-2). Recent clinical studies have shown the association between increased PDPN expression and poor disease prognosis, indicating that the establishment of anti-PDPN mAbs is critical for developing novel therapeutic strategies against cancer development and metastatic progression. This Special Issue of Cells should improve our understanding of PDPN by including researchers working not only with structure and function of PDPN but also diagnosis and therapy targeting PDPN, including antibody-drug conjugate (ADC), chimeric antigen receptor-T (CAR-T) therapy, radioimmunotherapy (RIT), photoimmunotherapy (PIT), and liquid biopsy.

Prof. Yukinari Kato
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • podoplanin (PDPN)
  • platelet aggregation
  • antibody
  • cancer

Published Papers

This special issue is now open for submission.
Back to TopTop